

MECHANISM OF ACTION OF THE NITROSOUREAS—IV

SYNTHESIS OF THE 2-HALOETHYLNITROSOUREA-INDUCED DNA CROSS-LINK 1-(3-CYTOSINYL),2-(1-GUANYL)ETHANE

JOSEPH G. MACFARLAND,* MARION C. KIRK† and DAVID B. LUDLUM*‡

*Department of Pharmacology, University of Massachusetts Medical School, Worcester, MA 01655;
and †Southern Research Institute, Birmingham, AL 35202, U.S.A.

(Received 16 February 1989; accepted 26 June 1989)

Abstract—The 2-haloethylnitrosoureas have been shown to form the cross-linked structure 1-(3-cytosinyl),2-(1-guanyl)ethane in DNA. This cross-link has now been synthesized by the reaction of O^6 -(2-fluoroethyl)guanosine with deoxycytidine in dimethyl sulfoxide followed by removal of the sugars by acid hydrolysis. This synthetic route supports the mechanism for cross-link formation in DNA that involves an initial attack on the O^6 -position of guanine, followed by a rearrangement and subsequent reaction with cytosine. It also provides a practical route to the synthesis of 1-(3-cytosinyl),2-(1-guanyl)ethane for studies involving formation of this cross-link in DNA.

The 2-haloethylnitrosoureas are antitumor agents whose biological activities apparently result from their ability to modify DNA [1, 2]. Specifically, their cytotoxic effects have been related to DNA cross-linking as determined by the alkaline elution technique [3]. Studies from our laboratory have shown that cross-linking can be attributed, at least in part, to formation of the structure 1-(3-cytosinyl),2-(1-guanyl)ethane [4].

1-(3-Cytosinyl),2-(1-guanyl)ethane is apparently formed in DNA by the 2-haloethylnitrosoureas following an initial attack on the O^6 -position of guanine. According to this scheme, an O^6 -substituted-guanine, e.g. O^6 -(2-fluoroethyl)guanine or O^6 -(2-chlorethyl)guanine, is formed initially and rearranges to the intermediate, 1, O^6 -ethanoguanine. 1, O^6 -Ethanoguanine then reacts with cytosine, probably in the opposite DNA strand, to yield $\text{CytCH}_2\text{CH}_2\text{Gua}$ § [4, 5]. This mechanism is supported by the observation that cells lacking in the ability to repair O^6 -alkylguanines are more sensitive to the cytotoxic action of the 2-haloethylnitrosoureas than cells which are able to remove these alkyl groups [6]. Also in agreement with this mechanism is the observation that O^6 -alkylguanine-DNA alkyltransferase prevents DNA cross-linking *in vitro*, as determined by physical measurements [7, 8]. Recently, we have shown that alkyltransferase specifically prevents formation of $\text{CytCH}_2\text{CH}_2\text{Gua}$ [9].

Here, we describe the synthesis of $\text{CytCH}_2\text{CH}_2\text{Gua}$ at the monomer level by a route which involves initial formation of $\text{dCydCH}_2\text{CH}_2\text{Guo}$ from the reaction of O^6 -(2-fluoroethyl)guanosine with deoxycytidine, as reported

previously in abstract form [10]. This synthetic scheme follows the mechanism proposed above and, therefore, strongly supports it as the route to cross-linking in DNA. The initial synthetic product, $\text{dCydCH}_2\text{CH}_2\text{Guo}$, is suitable for use as a hapten to produce antibodies for the detection of this cross-link in DNA, and as a source of marker material in HPLC separations.

MATERIALS AND METHODS

Materials. O^6 -(2-Fluoroethyl)guanosine was prepared as described previously from 6-chloro-2-aminopurine-9-riboside (PWA, Mannheim) [5]. Deoxycytidine was obtained from P-L Biochemicals (Milwaukee, WI); both nucleosides were dried by repeated washings with absolute ethanol and evaporations to dryness. Marker amounts of $\text{dCydCH}_2\text{CH}_2\text{dGuo}$ were isolated from DNA which had been reacted with N,N' -bis(2-chloroethyl)- N -nitrosourea [4]. Marker 1-(2-hydroxyethyl)guanosine was synthesized as described previously [5]; 3-methyldeoxycytidine was purchased from Calbiochem (San Diego, CA) and 1-methylguanosine from the Sigma Chemical Co. (St Louis, MO).

Reaction of O^6 -(2-fluoroethyl)guanosine with deoxycytidine. O^6 -(2-Fluoroethyl)guanosine (2 mg) was added to 40 μl of dimethyl sulfoxide containing 4 mg deoxycytidine, and the solution was incubated at 55° for 1 week. At the end of this time, it was added to 8 ml of water and the components were separated, 1 ml at a time, on a C_{18} column as described below. Increasing the time of incubation or the temperature, or adding pyridine or other bases did not seem to improve the yield significantly; the most important factor was the elimination of water.

High-performance liquid chromatography. HPLC separations were performed on a Spherisorb 5 μm (4.6×250 mm) C_{18} column from Alltech (Deerfield, IL). The column was eluted at 1 ml/min with a gradient of 1 to 10% acetonitrile in 50 mM KH_2PO_4 ,

‡ To whom correspondence should be addressed.

§ Abbreviations: $\text{CytCH}_2\text{CH}_2\text{Gua}$, 1-(3-cytosinyl),2-(1-guanyl)ethane; $\text{CytCH}_2\text{CH}_2\text{Guo}$, 1-(3-cytosinyl),2-(1-guanosinyl)ethane; $\text{dCydCH}_2\text{CH}_2\text{Guo}$, 1-(3-deoxycytidyl),2-(1-guanosinyl)ethane; $\text{dCydCH}_2\text{CH}_2\text{dGuo}$, 1-(3-deoxycytidyl),2-(1-deoxyguanosinyl)ethane; and FABMS, fast atom bombardment mass spectrometry.

pH 6, over 20 min, and then continued with 10% acetonitrile in the same buffer for 20 min. Elution profiles were monitored at 254 nm with a Hewlett-Packard 1040A detector system. This detector is interfaced with a Hewlett-Packard 85B computer and is able to record spectra of derivative peaks as they are separated, thus providing valuable information as to the purity and identity of absorbance peaks. Peak areas were recorded on a Hewlett-Packard 3390A integrating recorder.

Spectrometry. Ultraviolet spectra were obtained on a Beckman model 35 spectrophotometer in 0.1 HCl, in 0.1 M sodium cacodylate buffer, pH 7, and in 0.1 M NaOH. Fast atom bombardment mass spectrometry was performed on a Varian MAT 311A instrument using a sulfolane-glycerol matrix and an 8 keV beam of xenon atoms. The low volatility of the cross-linked structures makes it essential to remove all traces of sodium and potassium buffers; accordingly, derivatives were purified for mass spectrometry by elution from a C₁₈ column with dilute triethylammonium formate buffer, then reisolated from a C₁₈ column with a water-acetonitrile system, and finally dried over P₂O₅ *in vacuo*.

RESULTS

HPLC analyses of controls and of the reaction mixture of deoxycytidine and *O*⁶-(2-fluoroethyl)guanosine are shown in Fig. 1. Deoxycytidine was essentially stable under these conditions (Fig. 1A), but *O*⁶-(2-fluoroethyl)guanosine (peak 5 in Fig. 1B) gradually decomposed into two products labeled peaks 2 and 3. Peak 2 was shown to be 1-(2-hydroxyethyl)guanosine by co-chromatography with known marker material and by its ultraviolet spectra as described previously [5]. The new product, peak 3, had UV spectra in acid, base, and neutral pH identical with those of peak 2, indicating that it was a 1-substituted guanosine. Mass spectrometry of the purified derivative showed that it had a molecular weight of 329, in agreement with a structure of 1-(2-fluorethyl)guanosine for this derivative.

As shown in Fig. 1C, an additional product (peak 4) appeared when deoxycytidine was reacted with *O*⁶-(2-fluoroethyl)guanosine. This peak was collected and shown to consist of a single component by rechromatography on a C₁₈ column and by analysis on a strong cation exchange column. Its UV spectra, as shown in Fig. 2, were identical with those of 1-(3-deoxycytidyl),2-(1-deoxyguanosinyl)ethane [4]. FABMS revealed (*M* + 1) = 537 in agreement with the proposed structure 1-(3-deoxycytidyl),2-(1-guanosinyl)ethane for this compound.

Proof that we had synthesized 1-(3-deoxycytidyl),2-(1-guanosinyl)ethane came from an analysis of the acid hydrolysate of this compound and a comparison of the hydrolysis products with those of authentic 1-(3-deoxycytidyl),2-(1-deoxyguanosinyl)ethane isolated from DNA which had been reacted with *N,N'*-bis(2-chlorethyl)-*N*-nitrosourea.

Putative 1-(3-deoxycytidyl),2-(1-guanosinyl)ethane, isolated as shown in Fig. 1, was treated with 0.1 N HCl for 1 hr at 100° and then separated by HPLC under the same conditions as those used in




Fig. 1. HPLC profiles after incubation for 7 days at 55°: (A) deoxycytidine alone; (B) *O*⁶-(2-fluoroethyl)guanosine alone; and (C) a mixture of deoxycytidine and *O*⁶-(2-fluoroethyl)guanosine. See text for elution conditions and peak identifications.




Fig. 2. Ultraviolet spectra of 1-(3-deoxycytidyl),2-(1-guanosinyl)ethane in acidic (· · ·, pH 1), neutral (—, pH 7), and basic (---, pH 12) solution.

Fig. 1. As shown in Table 1, three major ultraviolet-absorbing peaks were observed with retention times of 15.9, 19.8, and 21.7 min; the last of these corresponded to unchanged peak 4 material as verified

Table 1. HPLC retention times and molecular weights of cross-linked structures as determined by mass spectrometry

Derivative	Retention time (min)	Mol. wt
CytCH ₂ CH ₂ Gua	15.9	288
CytCH ₂ CH ₂ Guo	19.8	420
dCydCH ₂ CH ₂ Guo	21.7	536
dCydCH ₂ CH ₂ dGuo	21.9	520




Fig. 3. Ultraviolet spectra of 1-(3-cytosinyl),2-(1-guanyl)ethane in acidic (···, pH 1), neutral (—, pH 7), and basic (---, pH 12) solution.




Fig. 4. Ultraviolet spectra of 1-(3-cytosinyl),2-(1-guanyl)ethane in acidic (···, pH 1), neutral (—, pH 7), and basic (---, pH 12) solution.

by its characteristic ultraviolet spectrum and its retention time. The two earlier peaks were collected for ultraviolet and mass spectrometry and were assigned the structures 1-(3-cytosinyl),2-(1-guanyl)ethane and 1-(3-cytosinyl),2-(1-guanyl)synethyl)ethane, respectively, as described below.

Material from the 19.8 min peak had the ultraviolet spectra shown in Fig. 3, while material in the 15.9 min peak had the spectra shown in Fig. 4.

FABMS revealed $(M + 1) = 421$ for the 19.8 min peak and $(M + 1) = 289$ for the 15.9 min peak, both of which are in agreement with the predicted molecular weights for the structures shown in Table 1. The 15.9 min peak had lost both the ribose and the deoxyribose sugars, while the 19.8 min peak had evidently lost the deoxyribose sugar from the substituted deoxycytidine but not the ribose sugar from the substituted guanosine.


Since we thought the purine nucleoside might be less stable than the pyrimidine nucleoside, we compared the stability of 1-methylguanosine with 3-methyldeoxycytidine (data not shown). These studies, performed spectrometrically, showed that 3-methyldeoxycytidine was less stable in an acidic solution than 1-methylguanosine.

Hydrolysis of dCydCH₂CH₂dGuo isolated from DNA under the same conditions used for hydrolysis of synthetic dCydCH₂CH₂Guo yielded a single ultraviolet-absorbing peak with a retention time of 15.9 min and the same ultraviolet spectra (shown in Fig. 4) as that obtained from synthetic 1-(3-deoxycytidyl),2-(1-guanyl)synethyl)ethane. The products were shown to be the same by co-chromatography on a C₁₈ column.

Thus, on the basis of the ultraviolet and mass spectrometric data and the fact that it could be acid hydrolyzed to the same product that we obtained by acid hydrolysis of dCydCH₂CH₂dGuo isolated from DNA, we concluded that we had synthesized dCydCH₂CH₂Guo from *O*⁶-(2-fluoroethyl)-guanosine and deoxycytidine. The yield of dCydCH₂CH₂Guo in the reaction whose analysis is shown in Fig. 1 was 13%, based on *O*⁶-(2-fluoroethyl)guanosine. Yields ranged up to 18% depending, apparently, on our success in excluding water from the reaction. The yield was not increased significantly by varying time and temperature, or by the addition of pyridine or other bases. A systematic study of other solvent systems was not undertaken, however.

DISCUSSION

The successful synthesis of CytCH₂CH₂Gua from *O*⁶-(2-fluoroethyl)guanosine and deoxycytidine shows that our proposed route to this cross-link in DNA, which involves an initial attack on the *O*⁶-position of guanine, is probably valid. Furthermore, since the presence of *O*⁶-(2-fluoroethyl)guanine has been demonstrated in DNA that was treated with *N,N'*-bis(2-fluoroethyl)-*N*-nitrosourea, at least some of the cross-links presumably arise from *O*²-(2-fluoroethyl)guanine, specifically [5]. This would not exclude the possibility that other intermediates involving some other residue of the parent 2-haloethylnitrosourea as a leaving group may also lead to cross-link formation. For example, attack on DNA by a cyclized form of *N,N'*-bis(2-fluoroethyl)-*N*-nitrosourea may lead to initial substitution at the *O*⁶-position of guanine by the



group [1, 11]. Alternatively, initial substitution at the *O*⁶-position of guanine may involve the $-\text{CH}_2\text{CH}_2\text{NNOH}$ group, as suggested by Buckley

and Brent [12]. Either of these *O*⁶-substituted guanines could probably form the intermediate 1,*O*⁶-ethanoguanine and lead to the CytCH₂CH₂Gua cross-link.

In this regard, recent studies of the reaction of *N,N'*-bis(2-chloroethyl)-*N*-nitrosourea with guanosine may be relevant [13]. These studies have shown that *N,N'*-bis(2-chloroethyl)-*N*-nitrosourea reacts with guanosine in the presence of bromide ion to form 7-bromoethylguanosine in addition to 7-chloroethylguanosine. This observation indicates that some of the initial substitution of guanosine involves a highly reactive intermediate.

It is also of interest to compare the slow rate of cross-link formation from *O*⁶-(2-fluoroethyl)-guanosine reported here (1 week at 55°) with the observation that *N,N'*-bis(2-fluoroethyl)-*N*-nitrosourea cross-links DNA in a few hours [14]. Although this difference may indicate that the cross-linking measured by Kohn [14] occurs by a different mechanism than that described here or that the difference in solvent affects the rate, it seems probable that steric factors are influencing the rate in DNA. The local DNA structure may bring the substituted guanine into a favourable position for reaction with cytosine and thereby accelerate the reaction.

In summary, we have described a relatively straightforward synthetic route to the DNA cross-link, CytCH₂CH₂Gua. A similar synthesis could be used to prepare 1-(3-deoxycytidyl),2-(1-deoxyguanosinyl)ethane, but this would require the use of the less readily available 6-chloro-2-aminopurine-9-deoxyriboside as a starting material rather than 6-chloro-2-aminopurine-9-riboside. Finally, the synthesis reported here offers further insight into the likely mechanism by which the CytCH₂CH₂Gua cross-link is formed in DNA.

Acknowledgements—This work was supported by Public Health Service Grant CA44499 from the National Cancer Institute and by Contract DAMD17-82-C-2203 from the United States Army Medical Research and Development Command.

REFERENCES

1. Ludlum DB and Tong WP, Modification of DNA and RNA bases by the nitrosoureas. In: *Nitrosoureas in Cancer Treatment* (Eds. Serrou B, Schein P and Imbach J-L), pp. 21–31. Elsevier/North Holland Biomedical Press, Amsterdam, 1981.
2. Ludlum DB and Tong WP, DNA modification by the nitrosoureas: chemical nature and cellular repair. In: *Experimental and Clinical Progress in Cancer Chemotherapy* (Ed. Muggia FM), pp. 141–154. Martinus Nijhoff, Boston, 1985.
3. Kohn KW, Erickson LC, Laurent G, Ducore J, Sharkey N and Ewig RA, DNA crosslinking and the origin of sensitivity to chloroethylnitrosoureas. In: *Nitrosoureas: Current Status and New Developments* (Eds. Prestayko AW, Crooke ST, Baker LH, Carter SK and Schein PS), pp. 69–83. Academic Press, New York, 1981.
4. Tong WP, Kirk MC and Ludlum DB, Formation of the cross-link, 1-[*N*³-deoxycytidyl],2-[*N*¹-deoxyguanosinyl]-ethane, in DNA treated with *N,N'*-bis(2-chloroethyl)-*N*-nitrosourea (BCNU). *Cancer Res* **42**: 3102–3105, 1982.
5. Tong WP, Kirk MC and Ludlum DB, Mechanism of action of the nitrosoureas—V. The formation of *O*⁶-(2-fluoroethyl)guanine and its probable role in the crosslinking of deoxyribonucleic acid. *Biochem Pharmacol* **32**: 2011–2015, 1983.
6. Erickson LC, Laurent G, Sharkey NA and Kohn KW, DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. *Nature* **288**: 727–729, 1980.
7. Robins P, Harris AL, Goldsmith I and Lindahl T, Cross-linking of DNA induced by chloroethyl-nitrosourea is prevented by *O*⁶-methylguanine–DNA methyltransferase. *Nucleic Acid Res* **11**: 7743–7758, 1983.
8. Brent TP, Suppression of cross-link formation in chloroethylnitrosourea-treated DNA by an activity in extracts of human leukemic lymphoblasts. *Cancer Res* **44**: 1887–1892, 1984.
9. Ludlum DB, Mehta JR and Tong WP, Prevention of 1-(3-deoxycytidyl),2-(1-deoxyguanosinyl)-ethane cross-link formation in DNA by *O*⁶-alkylguanine–DNA alkyltransferase. *Cancer Res* **46**: 3353–3357, 1986.
10. Ludlum DB, Direct synthesis of the haloethyl-nitrosourea-induced DNA lesion, 1-(3-Cytosinyl),2-(1-guanyl)ethane (CytCH₂CH₂Gua). *Proc Am Assoc Cancer Res* **27**: 233, 1986.
11. Tong WP and Ludlum DB, Mechanism of action of the nitrosoureas—III. Reaction of bis-chloroethyl nitrosourea and bis-fluoroethyl nitrosourea with adenosine. *Biochem Pharmacol* **28**: 1175–1179, 1979.
12. Buckley N and Brent TP, Structure–activity relations of (2-chloroethyl)nitrosoureas: 2. Kinetic evidence of a novel mechanism for the cytotoxicity important DNA cross-linking reactions of (2-chloroethyl)nitrosoureas. *J Am Chem Soc* **110**: 7520–7529, 1988.
13. Parker S, Kirk MC, Ludlum DB, Koganty RR and Lown JW, Reaction of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) with guanosine: evidence for a new mechanism of DNA modification. *Biochem Biophys Res Commun* **139**: 31–36, 1986.
14. Kohn KW, Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas. *Cancer Res* **37**: 1450–1454, 1977.